The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections

Clinical Infectious Diseases

Volumn 38, Issue 12, 2004, Pages 1673-1681

  Arbeit, Robert D ^a,c   Maki, Dennis ^b   Tally, Francis P ^a,d   Campanaro, Edward ^a   Eisenstein, Barry I ^a  

^a Cubist Pharmaceutical   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Transcept Pharmaceuticals Inc   (United States)

^d CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CLOXACILLIN; DAPTOMYCIN; FLUCLOXACILLIN; METRONIDAZOLE; NAFCILLIN; OXACILLIN; PENICILLIN G; VANCOMYCIN;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENTEROCOCCUS FAECALIS; FEMALE; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION COMPLICATION; KIDNEY DISEASE; LUNG DISEASE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY; MYALGIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS PYOGENES; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PENICILLINS; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 2942665465     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420818     Document Type: Article

References (33)

1. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999; 44(Suppl A):19-23.
2. Doern GV, Jones RN, Pfaller MA, Kugler KC, Beach ML. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). Diagn Microbiol Infect Dis 1999; 34:65-72.
3. National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, Issued August 2001. Atlanta: Centers for Disease Control and Prevention. Am J Infect Control 2001; 29:404-21.
4. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7:327-32.
5. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:565-7.
6. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36:2709-14.
7. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44:1062-6.
8. Snydman DR, Jacobus NV, McDermott LA, Lonks JR, Boyce JM. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother 2000; 44:3447-50.
9. Wise R, Andrews JM, Ashby JP. Activity of daptomycin against gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother 2001; 48: 563-7.
10. King A, Phillips I. The in vitro activity of daptomycin against 514 gram-positive aerobic clinical isolates. J Antimicrob Chemother 2001; 48:219-23.
11. Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467-70.
12. Barry AL, Fuchs PC, Brown SD. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45:1919-22.
13. Alborn WE Jr, Allen NE, Preston DA. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother 1991; 35:2282-7.
14. Allen NE, Alborn WE Jr, Hobbs JN Jr. Inhibition of membrane potential-dependent amino acid transport by daptomycin. Antimicrob Agents Chemother 1991; 35:2639-42.
15. Canepari P, Boaretti M, del Mar Lleo M, Satta G. Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032). Antimicrob Agents Chemother 1990; 34:1220-6.
16. Silverman JA, Perlmutter NG, Shapiro HM. Membrane depolarization and bactericidal activity are correlated for daptomycin [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001:111.
17. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother 2001; 45:1799-802.
18. Dvorchik BH, Brazier D, DeBruin MF. Daptomycin pharmacokinetics and safety in escalating doses administered once daily to healthy volunteers. Antimicrob Agents Chemother 2003; 47:1318-23.
19. Verhoef J. Daptomycin: a new agent to treat serious gram-positive infections [abstract S251]. In: Final programme of the 12th European Conference of Clincal Microbiology and Infectious Diseases (Milan, Italy). 2002.
20. NCCLS. Eleventh informational supplement. NCCLS document M100-S11. Villanova, PA: NCCLS, 2001.
21. NCCLS. Approved standard M2-A6. 7th ed. Wayne, PA: NCCLS, 1997.
22. Oleson FB Jr, Berman CL, Kirkpatrick JB, Regan KS, Lai JJ, Tally FP. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948-53.
23. US Food and Drug Administration/CFDER resources page. Food and Drug Administration Web site. DAIDP - points to consider - 1992 addendum. Available at: http://www.fda.gov/CDER/guidance/addendum .htm. Accessed 10 June 2003.
24. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infections. Clin Infect Dis 2003; 36:592-8.
25. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
26. Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162:2229-35.
27. Graffunder EM, Venezia RA. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 2002; 49: 999-1005.
28. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44:263-73.
29. Stevens DL, Smith LG, Bruss JB, et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44:3408-13.
30. Tally FP, Zeckel M, Wasilewski MM, et al. Daptomycin: a novel agent for gram-positive infections. Exp Opin Invest Drugs 1999; 8:1223-38. Available at: http://juno.ashley-pub.com/v1=4651405/cl=22/nw=1/ rpsv/cw/apl/13543784/v8n8/s7/ p1223.
31. Rubinstein E, Prokocimer P, Talbot GH. Safety and tolerability of quinupristin/dalfopristin: administration guidelines. J Antimicrob Chemother 1999; 44(Suppl A):37-46.
32. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62:425-41.
33. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34:695-8.